Advanced Biomed Inc. (ADVB) — Institutional Holders, Q4 2025
3 institutional investment managers reported a ADVB position on SEC Form 13F-HR for the quarter ended December 31, 2025, with a combined reported value of $9.2K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
ADVB in Q4 2025: what funds did
Funds that filed a 13F for both Q3 2025 and Q4 2025, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- UBS Group AGAdded · +965 sh+$282.00
Biggest sellers
- CITADEL ADVISORSSold out · -139,511 sh-$40.7K
- XTX Topco LtdTrimmed · -24,971 sh-$7.3K
ADVB 13F holders ranked 1–3 of 3
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q3 2025 |
|---|---|---|---|---|---|
| 1 | XTX Topco Ltd#1 · 27,264 sh | 27,264 | $8.0K | — | -47.8% |
| 2 | UBS Group AG#2 · 4,324 sh | 4,324 | $1.3K | — | +28.7% |
| 3 | Virtu Financial#3 · 12,561 sh | 12,561 | $4.00 | — | New |
Funds that sold out of ADVB in Q4 2025 (2)
Held ADVB at the end of Q3 2025 and filed a Q4 2025 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q3 2025 |
|---|---|---|
| CITADEL ADVISORS139,511 sh | 139,511 | $62.5K |
| HRT FINANCIAL35,681 sh | 35,681 | $15.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q4 2025. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q3 2025 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.